Their recent findings suggest (185) that the GLK-induced AhR-ROR-γt complex in Th17 may serve as a marker of IL-17A-mediated autoimmune disease and could be a new therapeutic target for human SLE and several diseases. This evidence concerns the gene MAP4K3 and systemic lupus erythematosus.